FDA approves anti-diarrheal drug for HIV/AIDS patients distributed by Salix The U.S. Food and Drug Administration approved Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Before treating patients with Fulyzaq, health care professionals should conduct proper testing to confirm the diarrhea is not caused by an infection or a gastrointestinal disease. Common side effects reported in patients taking Fulyzaq in the clinical trial were upper respiratory tract infection, bronchitis, cough, flatulence, and increased levels of the liver enzyme bilirubin. Fulyzaq is distributed by Salix Pharmaceuticals under license from Napo Pharmaceuticals.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.